Abbott Laboratories Aktie 903037 / US0028241000
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
|
15.10.2025 16:54:32
|
Abbott Laboratories Remains In Favor With London Investment Manager, New Filing Shows
CCLA Investment Management disclosed a purchase of 66,275 shares of Abbott Laboratories (NYSE:ABT) , estimated at ~$8.70 million based on the quarterly average price, in its SEC filing for the period ended September 30, 2025, filed on October 14, 2025.According to a filing with the Securities and Exchange Commission dated October 14, 2025, CCLA Investment Management increased its holding in Abbott Laboratories by 66,275 shares. The estimated value of the added shares was $8,700,002. This brings CCLA’s total position to 940,187 shares, worth $125.93 million at quarter-end.CCLA Investment Management increased its stake in Abbott Laboratories, which now represents 2.01% of fund AUM, outside its top five holdings.Continue readingWeiter zum vollständigen Artikel bei MotleyFool